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A report from the Keystone Symposium on Molecular and
Cellular Biology, ‘Omics Meets Cell Biology’, Breckenridge,
Colorado, 25-30 January, 2009.
A recent meeting in the Keystone series focused on the con-
vergence of two fields, large-scale biology ‘omics’ (defined as
anything with an ‘omic’ ending - genomics, proteomics,
metabolomics, and so on) and cell biology, including yeast,
mammalian tissue culture and animal models such as
Drosophila, Caenorhabditis elegans and mouse. Ruedi
Aebersold (Institute for Molecular Systems Biology, Zurich,
Switzerland) explained the concept as two groups of
researchers - the cell biologists who create islands of know-
ledge and the ‘omicists’ who try to connect these islands
together.
Screens based on RNA interference (RNAi) are now widely
used to uncover new members of signaling pathways and to
assess gene function. An interesting extension of the image
analysis typically used in cell-based RNAi screens was
presented by Lucas Pelkmans (Institute for Molecular
Systems Biology, Zurich, Switzerland) for screens designed
to uncover cellular factors affecting viral infectivity. He
showed that cell-based screens can be subject to a high
degree of variability, potentially due to heterogeneity in the
cell population. But by controlling for cell morphology and
density, biases in viral infection that had previously con-
founded the comparison between normal and RNAi-treated
cells, Pelkmans and colleagues were able to identify Dyrk
kinases as affecting the infectivity of a wide range of viruses.
Other screens identified components of cell organelle for-
mation. Laurence Pelletier (Samuel Lunenfeld Research
Institute, Toronto, Canada) presented an RNAi analysis of
114 proteins previously identified as being enriched to the
spindle pole in human cells. Forty of these gave statistically
consistent phenotypes affecting the spindle pole. One of
these, C14orf94, is part of a complex of eight proteins with
homology to the Augmin complex from Drosophila, three
other proteins of which were then also noted to be
phenotypic in the screen. Marta Lipinski (Harvard Medical
School, Boston, USA) presented an RNAi screen, using
image analysis, for proteins involved in regulating autophagy
(the digestion of a cell’s own organelles) in mammalian cells.
Lipinski concluded that this process was independent of the
protein kinase mTOR (mammalian target of rapamycin) and
appeared to be under the control of several signaling path-
ways, including that initiated by fibroblast growth factor,
and is thus much more diverse than in yeast, where
autophagy seems only to be dependent on TOR.
RNAi screens can also identify novel components in bio-
logical processes. Dan Durocher (Samuel Lunenfeld Research
Institute, Toronto, Canada) presented a re-analysis of a
published RNAi screen that has uncovered a new DNA
damage response gene, RNF168, involved in the RIDDLE
syndrome (radiosensitivity, immunodeficiency, dysmorphic
features and learning difficulties) in humans. Durocher
showed that the RNF168 protein could ubiquitinate H2AX
histones and acted downstream of the ubiquitin ligase RNF8
but upstream of MDC1 and the tumor suppressor BRCA1.
Joan Brugge (Harvard Medical School, Boston, USA) pre-
sented an RNAi-based screen in MCF-10A cells (a non-
tumorigenic human breast epithelial cell line) to find factors
that accelerate or inhibit collective cell migration, as
assessed by time-lapse video. Many novel regulators of the
cell adhesion molecule beta-catenin were uncovered. David
Sabatini (Massachusetts Institute of Technology, Cam-
bridge, USA) presented a pooled RNAi screen of the effects
on cell survival of 1,100 metabolic genes in various human
cancer cell lines. He found that cancer cells were more
sensitive than normal cells to the loss of enzymes involved in
metabolic detoxification processes, such as Nudix hydrolases
(which hydrolyze a variety of nucleoside diphosphate
derivatives) and enzymes involved in amino acid breakdown.
This is possibly because of higher levels of toxic inter-
mediates formed as a result of the higher metabolic rate of
cancer cells compared with normal somatic cells.Although great insight into many biological processes has
come from cell-based screens, complex developmental and
behavioral processes require animal models. Jennifer
Mummery Widmer (Institute for Molecular Biotechnology,
Vienna, Austria) presented a comprehensive analysis of
Notch signaling in Drosophila, using a large-scale RNAi
transgenic approach involving 20,000 lines and 11,000
genes. Widmer identified more than 170 new effectors of Notch
signaling, including proteins involved in vesicle trafficking,
nuclear import, and the COP9 complex, a general regulator
of protein degradation.
Ernst Hafen (Institute of Molecular Systems Biology, Zurich,
Switzerland) described a study in Drosophila that bridged
classical genetic screening and proteomic analysis. First, a
genome-wide random mutagenic screen uncovered 47 genes
involved in the regulation of head size. Hafen then directly
assayed the protein-protein interactions of these 47 genes.
Two genes giving a small head phenotype - Bunched and
Madam - were shown to interact; overexpressing both genes
together gave the complementary phenotype of a big head,
which was not observed when either was overexpressed
alone. Sabine Cordes (Samuel Lunenfeld Research Institute,
Toronto, Canada) discused an ethylnitrosourea-based
mutagenesis screen in mice that uncovered genes conferring
differential sensitivity to serotonin, a neurotransmitter that
has been associated with psychiatric disorders in humans.
She described the discovery of three genes - one conferring
hypersensitivity to serotonin, one conferring hyposensitivity,
and one conferring age-onset hyposensitivity.
The field of metabolomics is particularly challenging as more
than 106 different chemicals are estimated to be synthesized
in the body, excluding proteins, DNA and RNA. Edward
Dennis (University of California School of Medicine, San
Diego, USA) described the use of liquid chromatography/
mass spectrometry (MS) and custom-synthesized standards
to quantify 220 different eicosanoid lipids, which include the
prostaglandins and leukotrienes involved in inflammation.
The platform has been applied to the investigation of Toll-
like receptor signaling and Lyme disease. Peer Bork (EMBL,
Heidelberg, Germany) presented an example of the
integration of environmental and genomic data. Using meta-
genomic analysis, Bork analyzed a 1-cm deep block of soil at
2-mm intervals and found several regions with differing
metabolic potential. Uwe Sauer (Institute for Molecular
Systems Biology, Zurich, Switzerland) described the quanti-
tative monitoring of 250 metabolic enzymes in yeast by MS
under different growth conditions. Monitoring the flux of
metabolites showed that, although individual metabolites
were affected under different conditions, the net result of
metabolite flux was similar, with the exception of switches of
aerobic- versus fermentation-based metabolism.
Signaling networks have been difficult to elucidate, but the
application of quantitative proteomics and phosphoproteomics
is greatly advancing our understanding. Tony Pawson
(Samuel Lunenfeld Research Institute, Toronto, Canada)
presented an interesting study of bidirectional signaling in-
volving the neural cell adhesion molecules Ephs and
Ephrins. Using the technique of stable isotope labeling with
amino acids in cell culture (SILAC) they differentially
labeled cells expressing either protein, enabling measure-
ment of changes in intracellular phosphopeptides in the
presence or absence of signaling, as well as segregating Eph
and Ephrin signal cascades. An RNAi screen was then used
to functionally characterize the targets of Eph and Ephrin
signaling.
Aebersold presented work on defining kinase substrate
networks in yeast by phosphopeptide anlaysis in 120
different mutant kinase yeast lines. More than 900 differ-
entially phosphorylated targets of the tested kinases were
identified. In response to a question, Abersold said that
there were differences between mutation and pharmaco-
logical inactivation of the same kinase, as the mutant strain
is adapted to the loss whereas the pharmacological
inhibition is instantaneous. Steven Gygi (Harvard Medical
School, Boston, USA) described work aimed at identifying all
targets of the cell-cycle-dependent kinase Cdk1. He found
that Cdk1 target sites within compact protein domains were
highly conserved across 32 different yeast species, whereas
those in loops or disordered regions - 90% of all sites - were
poorly conserved.
Oliver Hantschel (Austrian Academy of Sciences, Vienna,
Austria) presented work using the immobilized tyrosine-
kinase inhibitors imatinib mesylate (Gleevec), bosutinib and
dasatinib as affinity reagents to isolate kinases from cell
lysates. Although bosutinib and dasatinib had higher affinity
than Gleevec for the kinase Abl1, they had far greater off-
target kinase activity, binding more than 70 different
kinases. Despite this, when cells with the Bcl-Abl trans-
location mutation were treated with the drugs, they had
similar transcriptional profiles, suggesting that the off-target
effects were not significant in the context of the cancer cell.
Garry Nolan (Stanford University, Stanford, USA) presented
a stunning single-cell analysis of signaling changes in
leukemias under different conditions, which had generated a
content-rich dataset that facilitated the subdivision of the
tumor into different tumor cell types based on the cells’
signaling potentials. Nolan showed that this system could
predict clinical outcomes through deep correlation mining.
He also described the development of a hybrid flow sorter/
mass spectrometer that, can routinely measure the binding
reactions of 14 different antibodies simultaneously, and has
a capacity of up to 50 different antibodies.
Structural biology has greatly expanded in the past decade
due to the establishment of several consortia. Cheryl Arrow-
smith (Ontario Cancer Institute, Toronto, Canada) presented
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colleagues have systematically solved the structures of more
than five E2 ligases to uncover their specificity for ubiquitin-
like molecules such as Sumo. They carried out sequence
clustering then solved representative cluster members. Next
they performed enzymatic assays on the majority of them to
classify their activities. Wolfgang Baumeister (Max Planck
Institute of Biochemistry, Martinsreid, Germany) presented
his work towards the goal of topological structural analysis
of cell systems, using cryo-electron tomography to generate
three-dimensional topological structures of macromolecules.
He then identifies different macromolecular complexes in
fixed cells, based on a library of topological structures.
A variety of useful resource websites were described at the
meeting, including LipidMaps [http://www.lipidmaps.org],
which provides data on lipid metabolic pathways and
synthesis, and the Protein Atlas [http://www.proteinatlas.
org], which aims to produce an antibody against every
protein in the human genome. Currently there are data for
antibodies against 6,000 genes; antibodies against the
20,000 known protein-coding genes is anticipated by 2010.
Other databases included a site containing genetic and
proteomics data on many aspects of cell migration and
motility [http://www.cellmigration.org], a new version of
the String protein-interaction network [http://string.embl.
de], the newest release of Cytoscape [http://www.cytoscape.
org], an open-source Java application for viewing a range of
data types as networks, and an update of Phosphositeplus
[http://www.phosphosite.org], a database that integrates
MS-observed phospho-peptides and other posttranslational
modifications with multi-species alignments and protein
structures.
At the end of the meeting there was a real impression that
stamp collecting in omics-based research was over (finally).
Research now involves function-based experimental design
combined with omics scale and technologies. Omics
technologies are no longer confined to the classical methods
of genomics, proteomics and transcriptomics, but now
include large-scale RNAi, overexpression, mutagenesis, and
small-molecule analysis. Nor is the field largely confined to
yeast, which in the past has been the staple of omics
researchers, as the majority of projects presented at the
meeting involved mammalian or insect cell culture and
model organisms such as fly, worm and mouse. It is
apparent that omics-based technologies have opened up cell
biology to a new era of investigation.
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